Short Interest in CapsoVision, Inc. (NASDAQ:CV) Grows By 35.2%

CapsoVision, Inc. (NASDAQ:CV) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 553,348 shares, an increase of 35.2% from the February 26th total of 409,160 shares. Based on an average daily volume of 199,118 shares, the short-interest ratio is currently 2.8 days. Approximately 1.2% of the company’s stock are short sold.

Hedge Funds Weigh In On CapsoVision

Hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund acquired a new stake in CapsoVision in the 3rd quarter worth approximately $34,000. Deutsche Bank AG acquired a new position in CapsoVision during the 4th quarter valued at approximately $47,000. Wells Fargo & Company MN raised its holdings in shares of CapsoVision by 66.4% in the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock worth $67,000 after buying an additional 2,508 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of CapsoVision during the third quarter worth $115,000. Finally, Virtu Financial LLC acquired a new stake in shares of CapsoVision during the fourth quarter worth $128,000.

CapsoVision Trading Down 0.3%

Shares of CV traded down $0.02 during midday trading on Friday, hitting $7.51. 288,209 shares of the company’s stock traded hands, compared to its average volume of 578,162. The stock has a market capitalization of $351.77 million and a price-to-earnings ratio of -3.43. CapsoVision has a 1 year low of $3.43 and a 1 year high of $15.37. The firm’s fifty day moving average is $5.58 and its 200-day moving average is $6.27.

CapsoVision (NASDAQ:CV) last announced its earnings results on Thursday, March 26th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $3.92 million for the quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on CV shares. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Wall Street Zen upgraded CapsoVision to a “hold” rating in a report on Saturday, January 10th. Finally, Benchmark reduced their price target on CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.